Sangamo Therapeutics, Inc.
General ticker "SGMO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $201.2M (TTM average)
Sangamo Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -4.0%.
Estimated limits based on current volatility of 6.0%: low 0.45$, high 0.51$
Factors to consider:
- Total employees count: 183 (-54.8%) as of 2024
- Top business risk factors: Regulatory and compliance, Financing risks, Manufacturing risks, Supply chain disruptions, Cybersecurity threats
- Current price 60.0% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.32$, 3.32$]
- 2025-12-31 to 2026-12-31 estimated range: [1.04$, 2.61$]
Financial Metrics affecting the SGMO estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.56 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 8.14 > -0.66
- Positive: Inventory ratio change, % of -11.56 <= -0.75
Short-term SGMO quotes
Long-term SGMO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $111.30MM | $176.23MM | $57.80MM |
| Operating Expenses | $312.58MM | $450.24MM | $161.77MM |
| Operating Income | $-201.28MM | $-274.00MM | $-103.97MM |
| Non-Operating Income | $9.43MM | $11.10MM | $5.86MM |
| R&D Expense | $249.90MM | $234.06MM | $111.52MM |
| Income(Loss) | $-191.85MM | $-262.90MM | $-98.11MM |
| Taxes | $0.43MM | $-5.07MM | $-0.17MM |
| Profit(Loss)* | $-192.28MM | $-257.83MM | $-97.94MM |
| Stockholders Equity | $294.96MM | $82.89MM | $22.77MM |
| Assets | $562.51MM | $165.32MM | $101.64MM |
| Operating Cash Flow | $-223.63MM | $-224.84MM | $-67.14MM |
| Capital expenditure | $20.17MM | $21.16MM | $0.27MM |
| Investing Cash Flow | $59.28MM | $153.53MM | $37.52MM |
| Financing Cash Flow | $84.66MM | $14.59MM | $28.38MM |
| Earnings Per Share** | $-1.25 | $-1.48 | $-0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.